Siglec‐1 and ‐2 as potential biomarkers in autoimmune disease

Eakin, Amanda; Bustard, Michael J; McGeough, Cathy; Ahmed, Tahanver; Bjourson, Anthony J.; Gibson, David

doi:10.1002/prca.201500069

Cited by 17 publications

(9 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SIGLEC1, also known as sialoadhesin or CD169, is a member of the immunoglobulin superfamily and is mainly expressed in macrophages, dendritic cells, and interferon-induced monocytes [ 37 , 38 ]. Studies have shown that CD169+ macrophages in TME can inhibit the progression of a variety of malignant tumors [ 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway

Liao

Huang

2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Phospholipase C epsilon 1 (PLCE1) is involved in the pathogenesis of many cancers. However, the biological role of PLCE1 in osteosarcoma (OS) is still poorly understood. The prognostic survival analysis was performed on the PLCE1gene in the TARGET data set and the differential expression of PLCE1 in OS tissue and normal bone tissue on the tissue chip was detected by immunohistochemistry. Spearman’s rank correlation coefficient analysis was implemented to explore the relationship between PLCE1 and immune genes. Finally, PLCE1 was silenced to explore its biological function in OS cells. The results of tissue chip immunohistochemistry showed that PLCE1 expression in OS tissue was higher than in normal bone tissue. The survival curve of PLCE1 and its corresponding receiver operating characteristic curve (ROC) showed that PLCE1 had a significant effect on the survival status of patients with OS and that the prognosis of patients with high PLCE1 expression was relatively poor. Spearman’s rank correlation coefficient analysis and qRT-PCR assays found that PLCE1 may promote immune escape from OS via CD70-CD27 signaling pathway. Silencing of PLCE1 causes the following biological behaviors of OS cells: it promotes apoptosis, inhibits proliferation of OS cells, and inhibits the ability of cell migration and invasion. PLCE1 is a poor prognostic marker and a potential key factor affecting the immune status of the OS tumor microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway

Liao

Huang

2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…This siglec mediates cell-cell interactions and the binding of immune cells to sialic acid-containing pathogens. CD169 is also used as a marker for a specific population of macrophages that not only have key roles in the initiation of antibacterial immune responses but are also involved in the transmission of some viruses and in the development of inflammation and several autoimmune diseases 90,94–96 .…”

Section: Glycans In Immunity and Inflammationmentioning

confidence: 99%

Glycosylation in health and disease

et al. 2019

View full text Add to dashboard Cite

The glycom e describes the complete repertoire of glycoconjugates com posed of carbohydrate chains, or glycans, that are covalently linked to lipid or protein molecules. Glycoconjugates are formed through a process called glycosylation and can differ in their glycan sequences, the connections between them and their length. Glycoconjugate synthesis is a dynamic process that depends on the local milieu of enzymes, sugar precursors and organelle structures as well as the cell types involved and cellular signals. Studies of rare genetic disorders that affect glycosylation first highlighted the biological importance of the glycome, and technological advances have improved our understanding of its heterogeneity and complexity. Researchers can now routinely assess how the secreted and cell-surface glycom es reflect overall cellular status in health and disease. In fact, changes in glycosylation can modulate inflammatory responses, enable viral immune escape, promote cancer cell metastasis or regulate apoptosis; the com position of the glycom e also affects kidney function in health and disease. New insights into the structure and function of the glycom e can now be applied to therapy developm ent and could improve our ability tofine-tune im m unological responses and inflammation, optimize the performance of therapeutic antibodies and boost immune responses to cancer. These examples illustrate the potential of the emerging field of 'glycomedicine'.

show abstract

“…Our exploration of the RNase-sensitivity of Siglec binding to cell surfaces suggests that the ligands of Siglec-11 and Siglec-14 are composed in part of glycoRNAs. Siglecs have been functionally associated with diseases such as autoimmunity and cancer (Eakin et al, 2016;Macauley et al, 2014;Mü ller et al, 2015). Several Siglec family members function as immune checkpoint receptors that signal through cytosolic immunoreceptor tyrosine-based inhibitory motifs (ITIMs), analogous to the T cell checkpoint receptor PD-1 (Riley, 2009).…”

Section: Regulatory Implications Of Cell Surface Glycornasmentioning

confidence: 99%